Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 12, 2012 - Issue 7
Submit an article Journal homepage
33
Views
0
CrossRef citations to date
0
Altmetric
Meeting Report

Finding gaps and building bridges in movement disorders

Alfonso Fasano Department of Neuroscience, Catholic University, Rome, Italy; Department of Neuroscience AFaR – Fatebenefratelli Association for Biomedical Research ‘San Giovanni Calibita-Fatebenefratelli’ Hospital, Isola Tiberina, Rome, Italy; Department of Neuroscience, Catholic University, Rome, Italy; Department of Neuroscience AFaR – Fatebenefratelli Association for Biomedical Research ‘San Giovanni Calibita-Fatebenefratelli’ Hospital, Isola Tiberina, Rome, Italy
,
Alberto J Espay Department of Neurology, UC Neuroscience Institute, Gardner Center for Parkinson’s Disease and Movement Disorders, University of Cincinnati, 260 Stetson St., Suite 2300 (PO Box 670525), Cincinnati, OH 45267, USA. [email protected]; Department of Neurology, UC Neuroscience Institute, Gardner Center for Parkinson’s Disease and Movement Disorders, University of Cincinnati, 260 Stetson St., Suite 2300 (PO Box 670525), Cincinnati, OH 45267, USA. [email protected]
&
Francesca Morgante Department of Neurosciences, Psychiatric and Anesthesiological Sciences, University of Messina, Italy; Department of Neuroscience, Catholic University, Rome, Italy
Pages 781-784 | Published online: 09 Jan 2014

References

  • Del Tredici K, Rüb U, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 61(5), 413–426 (2002).
  • Aguzzi A. Cell biology: beyond the prion principle. Nature 459(7249), 924–925 (2009).
  • Liu L, Drouet V, Wu JW et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7(2), e31302 (2012).
  • Pan-Montojo F, Anichtchik O, Dening Y et al. Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS ONE 5(1), e8762 (2010).
  • Abbott RD, Petrovitch H, White LR et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 57(3), 456–462 (2001).
  • Doherty KM, van de Warrenburg BP, Peralta MC et al. Postural deformities in Parkinson’s disease. Lancet Neurol. 10(6), 538–549 (2011).
  • Nutt JG, Bloem BR, Giladi N, Hallett M, Horak FB, Nieuwboer A. Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet Neurol. 10(8), 734–744 (2011).
  • Fasano A, Herzog J, Seifert E et al. Modulation of gait coordination by subthalamic stimulation improves freezing of gait. Mov. Disord. 26(5), 844–851 (2011).
  • Ferraye MU, Debû B, Fraix V et al. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson’s disease. Brain 133(Pt 1), 205–214 (2010).
  • Schüpbach WM, Agid Y. Psychosocial adjustment after deep brain stimulation in Parkinson’s disease. Nat. Clin. Pract. Neurol. 4(2), 58–59 (2008).
  • Schüpbach WM, Maltête D, Houeto JL et al. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology 68(4), 267–271 (2007).
  • Sciamanna G, Tassone A, Martella G et al. Developmental profile of the aberrant dopamine D2 receptor response in striatal cholinergic interneurons in DYT1 dystonia. PLoS ONE 6(9), e24261 (2011).
  • Chen G, Popa LS, Wang X et al. Low-frequency oscillations in the cerebellar cortex of the tottering mouse. J. Neurophysiol. 101(1), 234–245 (2009).
  • Carbon M, Argyelan M, Habeck C et al. Increased sensorimotor network activity in DYT1 dystonia: a functional imaging study. Brain 133(Pt 3), 690–700 (2010).
  • Munts AG, Van Rootselaar AF, Van Der Meer JN, Koelman JH, Van Hilten JJ, Tijssen MA. Clinical and neurophysiological characterization of myoclonus in complex regional pain syndrome. Mov. Disord. 23(4), 581–587 (2008).
  • Schrag A, Trimble M, Quinn N, Bhatia K. The syndrome of fixed dystonia: an evaluation of 103 patients. Brain 127(Pt 10), 2360–2372 (2004).
  • Lang AE, Chen R. Dystonia in complex regional pain syndrome type I. Ann. Neurol. 67(3), 412–414 (2010).
  • Tabrizi SJ, Reilmann R, Roos RA et al.; TRACK-HD investigators. Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 11(1), 42–53 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.